{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:25:28Z","timestamp":1782854728816,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012404","name":"Fuyang Normal University","doi-asserted-by":"publisher","award":["BSDZX2025004"],"award-info":[{"award-number":["BSDZX2025004"]}],"id":[{"id":"10.13039\/501100012404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274006"],"award-info":[{"award-number":["82274006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cbi.2026.111994","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:15:10Z","timestamp":1771949710000},"page":"111994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Inhibition of UDP-glucuronosyltransferases by fedratinib, implying a high risk of drug-drug interactions"],"prefix":"10.1016","volume":"430","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7084-3129","authenticated-orcid":false,"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Qv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-8186","authenticated-orcid":false,"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2026.111994_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cbi.2026.111994_bib2","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.cbi.2026.111994_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cbi.2026.111994_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cbi.2026.111994_bib5","series-title":"INREBIC (Fedratinib) Capsules, for Oral Use: US Prescribing Information","year":"2019"},{"key":"10.1016\/j.cbi.2026.111994_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00280-022-04464-w","article-title":"Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults","volume":"90","author":"Chen","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00280-020-04102-3","article-title":"Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach","volume":"86","author":"Ogasawara","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","article-title":"The UDP-Glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms","volume":"99","author":"Meech","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cbi.2026.111994_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.109.029660","article-title":"Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2026.111994_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-018-3665-x","article-title":"In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia","volume":"82","author":"Qosa","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.toxlet.2022.07.003","article-title":"In vitro effects of opicapone on activity of human UDP-glucuronosyltransferases isoforms","volume":"367","author":"Wang","year":"2022","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cbi.2026.111994_bib13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.21362","article-title":"Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver","volume":"44","author":"Trottier","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2026.111994_bib14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","article-title":"Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)","volume":"62","author":"Gagn\u00e9","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.toxlet.2021.05.004","article-title":"In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions","volume":"348","author":"Wang","year":"2021","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cbi.2026.111994_bib16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2026.111994_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2026.111994_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-020-04131-y","article-title":"Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib","volume":"86","author":"Wu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00280-019-03929-9","article-title":"Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia","volume":"84","author":"Ogasawara","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2026.111994_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2026.111994_bib22","series-title":"In Vitro Drug Interaction Studies \u2014 Cytochrome P450 enzyme- and transporter-mediated Drug Interactions Guidance for Industry","year":"2020"},{"key":"10.1016\/j.cbi.2026.111994_bib23","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2026.111994_bib24","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.3748\/wjg.v19.i38.6398","article-title":"New insights in bilirubin metabolism and their clinical implications","volume":"19","author":"Sticova","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cbi.2026.111994_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.apsb.2018.09.005","article-title":"Recent progress and challenges in screening and characterization of UGT1A1 inhibitors","volume":"9","author":"Lv","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.cbi.2026.111994_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/bdd.2241","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug-drug interactions","volume":"41","author":"Wang","year":"2020","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.cbi.2026.111994_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114592","article-title":"UGT1A1 dysfunction increases liver burden and aggravates hepatocyte damage caused by long-term bilirubin metabolism disorder","volume":"190","author":"Liu","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111994_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11910-022-01204-8","article-title":"Bilirubin encephalopathy","volume":"22","author":"Qian","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.cbi.2026.111994_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/15592294.2020.1795601","article-title":"Expression of UDP Glucuronosyltransferases 2B15 and 2B17 is associated with methylation status in prostate cancer cells","volume":"16","author":"Shafiee-Kermani","year":"2021","journal-title":"Epigenetics"},{"key":"10.1016\/j.cbi.2026.111994_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.fpc.0000197465.14340.d4","article-title":"Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir","volume":"16","author":"Boyd","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.cbi.2026.111994_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.09.007","article-title":"Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time","volume":"141","author":"Hulshof","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cbi.2026.111994_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00280-020-04084-2","article-title":"Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment","volume":"85","author":"Ogasawara","year":"2020","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972600102X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972600102X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:12:30Z","timestamp":1777439550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000927972600102X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["S000927972600102X"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2026.111994","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of UDP-glucuronosyltransferases by fedratinib, implying a high risk of drug-drug interactions","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2026.111994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111994"}}